TMO
Thermo Fisher Scientific Inc
Diagnostics & Research · Healthcare · United States
595.89
close · 2026-08-13
value
62
cheaper than peers62
quality
60
stronger fundamentals60
ranked against
Diagnostics & Research
value
quality
28 peers
Value inputs
| measure | company | vs peers |
| forward P/E | 21.66× | 71 |
| price to book | 4.18× | 60 |
| EV to EBITDA | 21.38× | 50 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 18.8% | 76 |
| return on equity | 13.5% | 67 |
| revenue growth | 10.5% | 48 |
| debt to equity | 80.6% | 33 |
4 of 4 measures available
Facts
| market cap | $220B |
| free cash flow | $6.24B |
| employees | 125,000 |
| first trade | 1980-03-17 |
| next earnings | 2026-07-23 |
| fundamentals updated | 2026-08-03 |